Description

Edratide (also known as TV 4710) is a precisely engineered synthetic 19-amino-acid peptide, based on the complementarity-determining region 1 (CDR1) of a human monoclonal anti-DNA antibody expressing the major idiotype 16/6 Id, which is associated with systemic lupus erythematosus (SLE) pathophysiology.

The peptide reproduces a key structural motif implicated in modulating immune cell survival and inflammatory pathways. In preclinical studies, Edratide reduces apoptosis, by downregulating the apoptotic initiator caspase-8 and executioner caspase-3, while upregulating the anti-apoptotic protein Bcl-xL. This regulatory shift can modulate autoreactive immune cell survival—a central feature in SLE disease models.

Edratide has demonstrated potential in numerous animal models of SLE, showing improvement in clinical and histological markers, including decreased autoantibody production, reduced renal immune complex deposition, and better survival compared with controls. Its immunomodulatory actions, via apoptosis regulation, highlight mechanisms relevant to B-cell tolerance, T-cell regulation, and immune-complex mediated pathology.

Manufactured under GMP-compliant conditions, Edratide is provided as a stable lyophilized peptide with exceptional purity (99.95%), supporting reproducible and robust research outcomes. Each batch includes a Certificate of Analysis (CoA) for identity and purity verification—essential for documentation in rigorous preclinical studies and GLP-adjacent research workflows.

Product Specifications

Mechanism of Action & Research Applications

Mechanism of Action

Edratide replicates a key immunoregulatory epitope found in the CDR1 region of a human anti-DNA idiotype. The peptide exerts anti-apoptotic and modulatory effects by influencing the caspase cascade and Bcl-xL expression. This shifts immune cells’ propensity for programmed cell death, affecting autoreactive B and T cell lifespans and influencing SLE-like pathology.

Research Applications

1. Systemic Lupus Erythematosus (SLE) Models

• Used to probe the role of apoptosis in SLE pathogenesis.

• Evaluated in mouse SLE models for its capacity to reduce nephritis severity, autoantibody titers, and glomerular immune complex deposition.

2. Apoptosis Signaling Studies

• Edratide helps dissect caspase-mediated pathways: it attenuates caspase-8 and caspase-3 activation and boosts Bcl-xL levels.

• Useful in identifying survival thresholds in immune cell populations.

3. Immune Tolerance & B-Cell Regulation

• Applied in studies of B-cell selection and tolerance, given its CDR1 origin from an idiotype with regulatory potential.

• May help model interventions that shift autoreactive clones toward survival or deletion.

4. Preclinical Drug Screening

• Serves as a reference peptide for screening small molecules or biologics targeting apoptotic or survival pathways in autoimmunity.

5. Immunotherapy Research

• Useful for exploring peptide-based tolerogens that alter pathogenic autoantibody production.

Development & Formulation Notes

Reconstitution & Handling

• Reconstitute lyophilized Edratide in sterile buffer (e.g., PBS) to desired stock concentration (commonly 1 mg/mL).

• Store aliquots at –20 °C; for long-term stability, keep at –80 °C.

• Avoid repeated freeze–thaw cycles.

Assay Design

• Common in vitro assays include measuring caspase activity, Bcl-xL expression, and apoptosis rates via annexin V or TUNEL assays.

• In vivo studies focus on renal histopathology, autoantibody levels, survival, and clinical scoring in lupus-prone strains.

Experimental Considerations

• Monitor dosing frequency and pharmacodynamics—frequent administration may be needed due to peptide metabolism.

• Check immune complex deposition and tissue-level caspase signaling to confirm efficacy.

Analytical Validation

• Confirm peptide integrity through HPLC and/or mass spectrometry as needed.

• Calibrate doses using peptide concentration assays or UV absorbance for accuracy.

  

Disclaimer

Edratide (TV 4710) is intended solely for laboratory research use. It is not approved for clinical, diagnostic, or therapeutic applications. The user is responsible for adherence to institutional and regulatory safety protocols. All described uses are research-context only and should not be construed as medical guidance or treatment recommendations.

Keywords

Edratide; TV 4710; CDR1 peptide; SLE research peptide; caspase modulator; apoptosis inhibitor peptide; Bcl-xL upregulation; autoimmune research tool; GMP-grade peptide; lupus mechanism peptide; complementarity-determining region 1 mimic; antigenic peptide.